Tremfya guselkumab patent expiration date?

Patents for Tremfya (guselkumab) are multiple and jurisdiction-specific, so there isn’t a single global expiration date. In short:

- United States: There is 12-year data exclusivity for biologics (BPCIA) from the first approval date, which for guselkumab is July 2017, so data exclusivity runs to July 2029. Individual patent term expirations (for composition-of-matter, formulation, method-of-use, etc.) vary and can be extended by patent term adjustments, typically placing some key patents in the late 2020s. Exact dates depend on which patent family you’re looking at.

- Europe and other regions: There are additional patent families and, in many cases, supplementary protection certificates (SPCs) that can extend protection into the 2030s, again depending on the jurisdiction and specific patent families.

If you want a precise date, tell me:
- the country/region (e.g., US, EU member state, etc.),
- which patent type you care about (composition-of-matter, method of use, formulation, etc.), and
- whether you want to include data exclusivity (US) as well.

I can then look up the current expiration dates from patent databases (Google Patents, USPTO, EPO) and give you a jurisdiction-by-jurisdiction summary.